Stocktoria
Vyome Holdings, Inc HIND
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-10-06
Vyome Holdings, Inc financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $319,714 | $8.0M | $8.7M | $11.2M | $13.6M | $11.3M | $3.3M | $9.1M | $9.9M | $3.4M |
| Gross profit | $218,771 | $194,970 | $5.5M | $6.8M | $8.3M | $6.3M | $331,000 | $3.7M | $5.1M | $584,000 |
| R&D expense | $588,258 | $285,391 | $2.3M | $2.5M | $2.4M | $3.5M | $6.9M | $10.7M | $10.6M | $9.9M |
| SG&A expense | $2.4M | $898,572 | $7.5M | $14.1M | $8.9M | $4.7M | $16.7M | $29.9M | $28.8M | $10.2M |
| Operating income | -$10.5M | -$1.0M | -$15.4M | -$46.4M | -$57.9M | -$12.5M | -$23.2M | -$37.0M | -$34.4M | -$19.5M |
| Income tax | — | $39,000 | $52,000 | -$380,000 | -$274,000 | -$181,000 | $14,000 | $11,000 | $10,000 | $2,000 |
| Net income | -$10.3M | -$1.4M | -$11.4M | -$46.2M | -$63.1M | -$21.6M | -$23.7M | -$37.4M | -$34.8M | -$20.5M |
| EPS (diluted) | $-4.86 | $-6001.39 | $-110.87 | $-108.90 | $-288.97 | $-5.55 | — | — | — | — |
| Operating cash flow | -$3.7M | -$614,136 | -$17.0M | -$21.9M | -$15.4M | -$8.6M | -$22.9M | -$29.4M | -$30.6M | -$19.4M |
| Free cash flow | — | — | — | — | — | -$8.7M | -$23.1M | -$30.7M | -$31.7M | -$19.7M |
| Cash & equivalents | $5.0M | $101,904 | $4.5M | $3.9M | $22.8M | $3.0M | $14.1M | $21.2M | $21.1M | $73.0M |
| Inventory | — | $2.5M | $3.7M | $3.6M | $3.0M | $2.2M | $1.9M | $1.6M | $1.4M | $827,000 |
| Total assets | $6.5M | $1.4M | $10.7M | $11.1M | $52.5M | $37.1M | $20.4M | $30.4M | $53.1M | $78.8M |
| Total liabilities | $2.7M | $5.8M | $4.0M | $7.5M | $8.2M | $22.6M | $4.5M | $17.3M | $18.0M | $14.5M |
| Shareholders' equity | $3.8M | -$4.4M | $6.7M | $3.7M | $44.3M | $14.5M | $24.1M | $13.1M | $35.1M | $64.3M |
Growth · year-over-year · Revenue CAGR -23.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -96.0% | -7.7% | -22.8% | -17.4% | +20.4% | +244.4% | -63.9% | -8.2% | +192.2% | -16.0% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.